Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 11:19 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 72 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Pulmonary Hypertension of Newborn Clear all
Terminated No phase listed Observational Accepts healthy volunteers

N-Terminal Pro-brain Natriuretic Peptide Hormone and Persistent Pulmonary Hypertension

NCT00443859
View directory record Official record
Conditions
Persistent Pulmonary Hypertension of Newborn
Interventions
Not listed
Lead sponsor
Christiana Care Health Services
Other
Eligibility
Up to 6 Months
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
2
States / cities
Newark, Delaware • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2016 · Synced Jul 22, 2026, 11:19 PM EDT
Terminated Not applicable Interventional Results available

Pharmacokinetic Study of Milrinone in Babies With Persistent Pulmonary Hypertension of the Newborn

NCT01088997
View directory record Official record
Conditions
Persistent Fetal Circulation Syndrome
Interventions
Milrinone Lactate
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
Up to 10 Days
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
2
States / cities
Detroit, Michigan • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2016 · Synced Jul 22, 2026, 11:19 PM EDT
Enrolling by invitation No phase listed Observational

Global Utilization And Registry Database for Improved preservAtion of doNor LUNGs

NCT04930289
View directory record Official record
Conditions
Interstitial Lung Disease, COPD, Cystic Fibrosis, Pulmonary Fibrosis, Pulmonary Arterial Hypertension, Emphysema
Interventions
LungGuard, BAROGuard
Device
Lead sponsor
Paragonix Technologies
Industry
Eligibility
Not listed
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
14
States / cities
Phoenix, Arizona • San Francisco, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Jul 22, 2026, 11:19 PM EDT
Completed No phase listed Observational

Pulmonary Hypertension in Trisomy 21 Patients

NCT00478296
View directory record Official record
Conditions
Congenital Disorders
Interventions
Not listed
Lead sponsor
Children's Healthcare of Atlanta
Other
Eligibility
Up to 8 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Jul 22, 2026, 11:19 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

A Prospective Longitudinal Observational Cohort Study of Pregnant Women Residing at High Altitude in Bolivia

NCT07312227
View directory record Official record
Conditions
Hypertensive Disorder of Pregnancy, Pulmonary Arterial Hypertension, Intrauterine Growth Restriction
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Jul 22, 2026, 11:19 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Inhaled Nitric Oxide for Pulmonary Hypertension and Bronchopulmonary Dysplasia

NCT03576885
View directory record Official record
Conditions
Pulmonary Hypertension, Bronchopulmonary Dysplasia
Interventions
inhaled nitric oxide, Placebo
Drug
Lead sponsor
AdventHealth
Other
Eligibility
23 Weeks to 29 Weeks
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Jul 22, 2026, 11:19 PM EDT
Recruiting Not applicable Interventional

Ventilator Pressure and Optimization of Compliance and Hemodynamics

NCT06512935
View directory record Official record
Conditions
Bronchopulmonary Dysplasia, Pulmonary Hypertension Due to Lung Diseases and Hypoxia, Extreme Prematurity, Ventilator Lung; Newborn, Ventilation Perfusion Mismatch
Interventions
Increase in the PEEP followed by decrease in the PEEP, Decrease in the PEEP followed by increase in the PEEP
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
7 Days to 30 Days
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 10, 2026 · Synced Jul 22, 2026, 11:19 PM EDT
Completed Not applicable Interventional

Safety and Effectiveness of a Virtual Pediatric Cardiac Rehabilitation Program or Telerehabilitation in Children With Heart Disease

NCT06819059
View directory record Official record
Conditions
Congenital Abnormalities, Pulmonary Arterial Hypertension (PAH), Orthotopic Heart Transplant, Cardiac Rehabilitation, Pediatric Cardiology, Telehealth, Telerehabilitation
Interventions
Pediatric Cardiac Telerehabilitation, Fitness Tracker Only
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
10 Years to 25 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 10, 2025 · Synced Jul 22, 2026, 11:19 PM EDT
Completed No phase listed Observational

Novel Echocardiographic Methods for Early Identification of Neonates at Risk for Chronic Pulmonary Hypertension

NCT04402645
View directory record Official record
Conditions
Pulmonary Hypertension, Infant, Premature
Interventions
Not listed
Lead sponsor
Mount Sinai Hospital, Canada
Other
Eligibility
14 Days and older
Enrollment
350 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Jun 13, 2024 · Synced Jul 22, 2026, 11:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Risk Factors, Costs, and Impacts of ED Boarding

NCT07532564
View directory record Official record
Conditions
Stroke (CVA) or TIA, Diabetes, Asthma (Diagnosis), COPD (Chronic Obstructive Pulmonary Disease), Sepsis, Hypertension, Heart Failure, Pneumonia, Urinary Tract Infection (Diagnosis), Chest Pain, Psychiatric Disorder, Sickle Cell Disease (SCD)
Interventions
Not listed
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
30,486 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Jul 22, 2026, 11:19 PM EDT
Terminated Phase 2 Interventional Results available

Study of Sildenafil to Treat Newborns With Persistent Pulmonary Hypertension

NCT01409031
View directory record Official record
Conditions
Persistent Pulmonary Hypertension, Respiratory Failure
Interventions
Intravenous Sildenafil, Placebo
Drug · Other
Lead sponsor
University of Colorado, Denver
Other
Eligibility
Up to 72 Hours
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
7
States / cities
Aurora, Colorado • Chicago, Illinois • Buffalo, New York + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2019 · Synced Jul 22, 2026, 11:19 PM EDT
Terminated Phase 2 Interventional

Hospital-Based Program for Treatment of Severe Cardiopulmonary Disease With Inhaled Nitric Oxide

NCT00041574
View directory record Official record
Conditions
Pulmonary Hypertension, Lung Disease, Sickle Cell Disease, Cardiac Transplant, Lung Transplant
Interventions
Inhaled Nitric Oxide
Drug
Lead sponsor
Mallinckrodt
Industry
Eligibility
5 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
3
States / cities
Denver, Colorado • Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 8, 2016 · Synced Jul 22, 2026, 11:19 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Sitaxentan Sodium (Thelin™) in Patients With Pulmonary Arterial Hypertension

NCT00080457
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
sitaxsentan sodium
Drug
Lead sponsor
Encysive Pharmaceuticals
Industry
Eligibility
12 Years to 75 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 8, 2007 · Synced Jul 22, 2026, 11:19 PM EDT
Completed No phase listed Observational

Evaluation of Patients With Known or Suspected Heart Disease

NCT00001313
View directory record Official record
Conditions
Peripheral Artery Disease, Coronary Disease, Diabetes and Heart Failure, Dilated Cardiomyopathy, Heart Failure, Renal Artery Stenosis, Pulmonary Hypertension
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2009
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Jul 22, 2026, 11:19 PM EDT
Completed Phase 1 Interventional

Quantifying the Presence of Lung Disease and Pulmonary Hypertension in Children With Sickle Cell Disease

NCT01895998
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
Albuterol
Drug
Lead sponsor
Duke University
Other
Eligibility
5 Years to 12 Years
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Jul 22, 2026, 11:19 PM EDT
Terminated Phase 4 Interventional

Inhaled Iloprost for the Treatment of Persistent Pulmonary Hypertension in the Term and Near Term Infants.

NCT00409526
View directory record Official record
Conditions
Pulmonary Hypertension
Interventions
Inhaled Iloprost
Drug
Lead sponsor
University of Chicago
Other
Eligibility
Up to 7 Days
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 1, 2014 · Synced Jul 22, 2026, 11:19 PM EDT
Recruiting Phase 2 Interventional

A Study of ROC-101 in Patients With Pulmonary Arterial Hypertension (PAH) and Pulmonary Hypertension Associated With Interstitial Lung Disease (ILD-PH) (ROCSTAR STUDY)

NCT07175038
View directory record Official record
Conditions
Pulmonary Arterial Hypertension (PAH), Pulmonary Hypertension, Interstitial Lung Disease
Interventions
ROC-101
Drug
Lead sponsor
AllRock Bio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
10
States / cities
Phoenix, Arizona • Rancho Cordova, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Jul 22, 2026, 11:19 PM EDT
Terminated No phase listed Observational

Evaluating Right Ventricular (RV) Size and Function Using the Upper Valley RV Algorithm and Novel Imaging Modalities

NCT03935178
View directory record Official record
Conditions
Pulmonary Hypertension, Valvular Heart Disease, Congenital Heart Disease, Congestive Heart Failure, Pulmonary Embolism, Acute Coronary Syndrome
Interventions
Measuring Right Ventricular Size and Function
Diagnostic Test
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Apr 5, 2022 · Synced Jul 22, 2026, 11:19 PM EDT
Terminated Phase 2 Interventional Results available

Sildenafil Therapy for Pulmonary Hypertension and Sickle Cell Disease

NCT00492531
View directory record Official record
Conditions
Sickle Cell Disease, Pulmonary Hypertension
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
12 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
8
States / cities
Oakland, California • Denver, Colorado • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2016 · Synced Jul 22, 2026, 11:19 PM EDT
Enrolling by invitation No phase listed Observational

International Registry of Congenital Portosystemic Shunt (IRCPSS)

NCT06041906
View directory record Official record
Conditions
Congenital Portosystemic Shunt, CPSS (Congenital Portosystemic Shunt)
Interventions
Shunt Closure
Procedure
Lead sponsor
Prof. Valérie Mc Lin
Other
Eligibility
1 Day and older
Enrollment
500 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
2
States / cities
New Haven, Connecticut • Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Jul 22, 2026, 11:19 PM EDT
Completed No phase listed Observational Accepts healthy volunteers Results available

Cardiovascular Complications of Sickle Cell Disease

NCT01044901
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
MRI, Transthoracic Echocardiography, tonometry, EKG
Procedure
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 22, 2022 · Synced Jul 22, 2026, 11:19 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

Hyperpolarized 129Xe MR Imaging of Lung Function in Healthy Volunteers and Subjects With Pulmonary Disease

NCT04624490
View directory record Official record
Conditions
Asthma, COPD, Interstitial Lung Disease, Cystic Fibrosis, Pulmonary Hypertension, Pulmonary Infection, Other Lung Disease
Interventions
Hyperpolarized Xe129
Drug
Lead sponsor
Mario Castro, MD, MPH
Other
Eligibility
3 Years and older
Enrollment
260 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2028
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Jul 22, 2026, 11:19 PM EDT
Terminated Phase 2 Interventional Results available

Inhaled Prostaglandin E1 (IPGE1) for Hypoxemic Respiratory Failure (NHRF)

NCT01467076
View directory record Official record
Conditions
Prematurity, Respiratory Insufficiency, Pulmonary Hypertension, Respiratory Distress Syndrome, Newborn
Interventions
Aerosolized Normal Saline, Inhaled PGE1
Drug
Lead sponsor
NICHD Neonatal Research Network
Network
Eligibility
Up to 7 Days
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
11
States / cities
Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 8 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Jul 22, 2026, 11:19 PM EDT
Completed No phase listed Observational

Phosphodiesterase Type-5 Inhibitor Therapy in Sickle Cell People With Pulmonary Hypertension

NCT03572036
View directory record Official record
Conditions
Pulmonary Hypertension, Sickle Cell Disease
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 18, 2021 · Synced Jul 22, 2026, 11:19 PM EDT